Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-24-048239
Filing Date
2024-12-03
Accepted
2024-12-03 08:03:46
Documents
8
Period of Report
2025-01-23

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20035571x1_def14a.htm DEF 14A 817720
2 logo_galectin.jpg GRAPHIC 26119
3 ny20035571x1_pvpchart1.jpg GRAPHIC 140847
4 ny20035571x1_pvpchart2.jpg GRAPHIC 120414
5 sig_jlewis.jpg GRAPHIC 12813
6 sig_jwcallicutt.jpg GRAPHIC 17818
7 ny20035571x1_pc01.jpg GRAPHIC 554419
8 ny20035571x1_pc02.jpg GRAPHIC 526357
  Complete submission text file 0001140361-24-048239.txt   2743802
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

EIN.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-31791 | Film No.: 241521213
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)